Summary of Phd thesis: Clinical, subclinical features and resistance to tyrosine kinase inhibitor of lung cancer patients with EGFR mutations

To describe the clinical and subclinical features of lung cancer patients with EGFR mutations before TKIs therapy and in the relapsed period. To identify the T790M mutation and MET amplification in patients with lung cancer and EGFR-TKIs resistance and the relationship with clinical and subclinical features.